Liverpool, England – A research paper published in Nature Cancer details new insights into the role of efferocytosis – the burying of dead cells – in pancreatic cancer that spreads to the liver. Liver metastasis occurs in 40–50% of people with pancreatic ductal adenosarcoma (PDAC), and there are currently no...
Latest News
Tokyo, Japan – Scientific advances in the last century have changed our world significantly. For example, the world of genetics has opened doors to a myriad of possibilities: augmented human capabilities, cures for diseases, and even changes to the course of evolution. In a study published last month in Communications...
Washington D.C. – The Global Alzheimer’s Platform Foundation®, (GAP) is releasing the first results from the Bio-Hermes-001 Study. This study in over 1000 community-based participants from throughout the US compared the results of blood and digital biomarkers with brain amyloid PET scans or cerebrospinal fluid assays. The study revealed a...
Odense, Denmark – Over the past two decades, immunotherapy – utilizing the body’s own immune system to combat illness – has emerged as a groundbreaking treatment for various types of cancer. The body’s own T-cells possess a remarkable capacity to identify and fight a wide range of cancers. Regrettably, cancer...
Alexander disease is a progressive and rare neurological disorder with no cure or standard course of treatment. But a new study led by researchers at the University of Wisconsin–Madison involving a rat model of the disease offers a potential treatment for the typically fatal condition. It’s a significant step in...
MDUK is delighted to bring you the news that a highly complex, innovative gene therapy is to become available on the NHS in England for the treatment of spinal muscular atrophy (SMA) Type 1. Babies born with SMA Type 1, the most common form of the condition, are unable to...
NEW YORK, NY — Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule oncology approaches with immunotherapeutic effects, today announced that the pre-specified efficacy requirement of its Phase 2 study of PT-112 for recurrent thymoma has been exceeded. Patients with recurrent thymoma have limited options for standard of care treatment, and...
MELBOURNE, Australia — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel treatments for chronic diseases such as recurrent and metastatic cancer, today announced that the Company and its joint research partners at the Universities of Jaén and Granada published key findings in a peer...
MELBOURNE, Australia — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today highlights the potential of its lead asset, PRP, as a novel therapeutic approach to the treatment and prevention of metastatic cancer...
Garden City, NY — ProPhase Labs Inc. (NASDAQ: PRPH), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. The Company is aiming for commercial launch in the second half of 2024. Ted Karkus, CEO of ProPhase Labs,...